Flatiron Health to Showcase Eight Abstracts at IASLC 2025 World Conference on Lung Cancer

Flatiron Health will present eight abstracts on real-world data and AI research at the IASLC 2025 World Conference on Lung Cancer. Highlights include the first published research using the Flatiron Health-Caris Life Sciences Clinical-Molecular Database to identify a gene signature predicting liver metastasis in NSCLC patients. Other research includes ongoing gaps in biomarker testing and new insights into NSCLC management in the UK.

Flatiron Health, a healthtech company specializing in oncology, has announced that eight abstracts leveraging its high-quality multimodal data will be presented at the IASLC 2025 World Conference on Lung Cancer, held in Barcelona, Spain. The conference, hosted by the International Association for the Study of Lung Cancer, will showcase how advanced AI practices can illuminate treatment patterns, measure effectiveness, and identify areas needing innovation in lung cancer care.

One of the highlights of Flatiron Health's presentation is the first published research using the Flatiron Health-Caris Life Sciences Clinical-Molecular Database (CMDB). This research aims to identify a novel gene signature that predicts the risk of liver metastasis in patients with advanced non-small cell lung cancer (NSCLC). By integrating high-quality clinical data with comprehensive molecular profiling, this study addresses a critical unmet need, providing clinicians with a new tool to identify high-risk patients and potentially enable more personalized surveillance and treatment strategies [1].

Additionally, Flatiron Health will present a poster highlighting ongoing gaps in biomarker testing after assessing over 13,000 patients with NSCLC in the US and UK. Another poster will provide new insights into how NSCLC is managed in the UK, including details on the most commonly used treatments, patterns in biomarker testing, and overall survival outcomes.

Instil Bio, Inc., a clinical-stage biopharmaceutical company, has also reported its second-quarter 2025 financial results and provided a corporate update. The company announced that the Investigational New Drug (IND) application for AXN-2510/IMM2510 ("2510") was cleared by the U.S. FDA in July. Updated '2510' monotherapy data in squamous-NSCLC will be presented at the IASLC's 2025 World Conference on Lung Cancer [2].

These presentations and financial updates underscore the ongoing advancements in lung cancer research and treatment, emphasizing the importance of real-world data and AI in driving innovation and improving patient outcomes.

References:
[1] https://www.businesswire.com/news/home/20250813223582/en/Flatiron-Health-Announces-Research-to-Be-Presented-at-IASLC-2025-World-Conference-on-Lung-Cancer-Hosted-by-the-International-Association-for-the-Study-of-Lung-Cancer
[2] https://finance.yahoo.com/news/instil-bio-reports-second-quarter-100000027.html